Aruna Bio, Inc.

BOSTON and ATHENS, Ga., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the U.S. Patent and Trademark Office has allowed U.S. Patent Application No. 17/238760, entitled Neural Cell Extracellular Vesicles, with method of use claims pertaining to its lead program, AB126, for the treatment of neuro-inflammatory diseases. AB126 is an exosome derived from proprietary neural stem cells and has been shown to reduce inflammation in the brain. This patent contains broad claims for the method of using AB126 to treat multiple indications where neuroinflammation is the primary pathological driver of the neurological disease. This includes neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), prion disease, motor neuron disease (MND), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA). The method claims also include multiple routes of administration including intravenous, intranasal, intrathecal, intraperitoneal, oral, and direct delivery into the brain. “We are excited to announce allowance of this method of use patent, as it validates the broad utility of our proprietary exosome platform for the treatment of neuroinflammatory conditions,” said Steven Stice, Ph.D., Co-Founder and Chief Scientific Officer of Aruna. “As we continue to strengthen our robust patent portfolio, expanding its breadth of claims across indications and extending its protection, we are also preparing to advance in the clinic.” About Aruna Bio Aruna Bio is revolutionizing CNS treatment with its proprietary neural exosome platform, targeting neurological conditions such as ALS, Alzheimer's, and stroke. Their lead product, AB126, demonstrates multiple biological activities, including crossing the blood-brain barrier, neuroprotection, and reducing neuro-inflammation, with potential for broad applicability across neurological diseases. The company's in-house cGMP facility supports their pipeline from early development to clinical trials. Aruna Bio's strategic approach includes leveraging their platform for drug delivery and exploring combination therapies, setting a foundation for addressing unmet needs in CNS treatment. Investor Contact: Corey Davis, Ph.D.LifeSci Advisors212-915-2577cdavis@lifesciadvisors.com

On track to initiate Phase 1b/2a clinical trial of AB126 in acute ischemic stroke in 2H 2024BOSTON and ATHENS, Ga., July 16, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the U.S. Patent and Trademark Office issued Patent No. 11,993,787, entitled Neural Cell Extracellular Vesicles, for lead program, AB126, an exosome derived from proprietary neural stem cells. AB126 has demonstrated an innate ability to traverse the blood brain barrier, with evidence of anti-inflammatory and neuroprotective properties. The patent is projected to extend the protection covering the composition of matter for AB126 and products for gene therapy using AB16, at least into 2038. “We are pleased to announce the issuance of this patent, which adds to our robust patent portfolio and supports our proprietary exosome platform for the treatment of neurological and other conditions,” said Steven Stice, Ph.D., Co-Founder and Chief Scientific Officer of Aruna. “We remain on track to initiate our Phase 1b/2a clinical trial for AB126 in acute ischemic stroke in the second half of 2024. Additionally, with this patent, which will provide a long runway, we will continue to explore the full potential of neural exosomes and expand its potential reach across indications, including amyotrophic lateral sclerosis. Importantly this patent protects Aruna Bio’s leading position in generating unmodified neural exosomes intended for therapeutic areas. This includes future gene therapies delivered via neural exosomes.” About the Phase 1b/2a Clinical Trial The planned dose-ascending clinical trial will evaluate the safety, tolerability, and preliminary efficacy of AB126 in patients with an acute ischemic stroke that have undergone a thrombectomy. Patients will receive three intravenous injection treatments of AB126 at a low, medium, and high dose. Patients with a poor prognosis post thrombectomy will be enrolled in the trial. About Aruna Bio Aruna Bio is revolutionizing CNS treatment with its proprietary neural exosome platform, targeting neurological conditions such as ALS, Alzheimer's, and stroke. Their lead product, AB126, demonstrates multiple biological activities, including crossing the blood-brain barrier, neuroprotection, and reducing neuro-inflammation, with potential for broad applicability across neurological diseases. The company's in-house cGMP facility supports their pipeline from early development to clinical trials. Aruna Bio's strategic approach includes leveraging their platform for drug delivery and exploring combination therapies, setting a foundation for addressing unmet needs in CNS treatment. Investor Contact: Corey Davis, Ph.D.LifeSci Advisors212-915-2577cdavis@lifesciadvisors.com

BOSTON and ATHENS, Ga., June 03, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced the appointment of Lynn Swann to its Board of Directors. “It is a pleasure to welcome Lynn, a former NFL player, Hall of Famer, broadcaster, politician and athletic director, to our Board of Directors,” said Bill Griffin, Chairman of the Board at Aruna Bio. “This is a key moment for Aruna as we prepare to initiate a Phase 1b/2a clinical trial with AB126, our lead program and the first exosome therapy to enter human clinical trials for a neurological indication. Beyond this Phase 1b/2a clinical trial in acute ischemic stroke, which is expected to start in the second half of 2024, we look forward to exploring the therapeutic feasibility of our platform across other indications, including traumatic brain injury and amyotrophic lateral sclerosis. Lynn’s support will be invaluable as we continue to work towards overcoming the limitations of current CNS treatments and build on the growing evidence demonstrating AB126’s anti-inflammatory and neuroprotective properties.” Mr. Swann added, “Joining Aruna is an exciting opportunity to bring potentially transformative therapies to people suffering from neurological conditions. Having witnessed concussions on the football field firsthand, I am delighted to contribute to the process of finding solutions for neurodegenerative conditions. I look forward to working with the outstanding management team and Board of Directors to drive forward AB126, which could potentially foster neuroprotection and promote neuro-regeneration following acute brain injuries as well as for long-term chronic diseases.” Lynn Swann is an American former football player, broadcaster, politician, and athletic director, best known for his association with the University of Southern California and the National Football League, Pittsburgh Steelers. Mr. Swann currently serves on the Board of Directors of Athene Holding Ltd. (ATH), Apollo Global Management (AGM) and American Homes 4 Rent (AMH), a leading large-scale owner and developer of single-family rental homes. In 2006, he was a nominee for Governor of Pennsylvania. With the Steelers, Mr. Swann won four Super Bowls, was selected to three Pro Bowls, and was named MVP of Super Bowl X. Mr. Swann was inducted into the Pro Football Hall of Fame in 2001 and the College Football Hall of Fame in 1993. About Aruna Bio Aruna Bio is revolutionizing CNS treatment with its proprietary neural exosome platform, targeting neurological conditions such as ALS, Alzheimer's, and stroke. Their lead product, AB126, demonstrates multiple biological activities, including crossing the blood-brain barrier, neuroprotection, and reducing neuro-inflammation, with potential for broad applicability across neurological diseases. The company's in-house cGMP facility supports their pipeline from early development to clinical trials. Aruna Bio's strategic approach includes leveraging their platform for drug delivery and exploring combination therapies, setting a foundation for addressing unmet needs in CNS treatment. Investor Contact: Corey Davis, Ph.D.LifeSci Advisors212-915-2577cdavis@lifesciadvisors.com